Senetek plc

Senetek PLC is a science-driven biotechnology company that develops, manufactures and markets proprietary solutions for aging-related healthcare problems. Three Diversified & Significant Business Opportunities: Senetek’s future growth and profitability are not dependent on a single product or market segment. Indeed, Senetek business divisions include three separate, distinct and significant opportunities in biopharmaceuticals, autoinjectable drug delivery systems and cosmeceuticals. INVICORPTM is a self-injectable formulation of vasoactive intestinal polypeptide (VIP) in combination with the adrenergic antagonist drug phentolamine mesylate (PMS) for treating ED (Erectile Dysfunction). An erection is achieved as soon as sexual stimulation begins, whether it is one minute or two hours after using INVICORP. INVICORP is delivered using a novel and patented system -- ReliaJect® -- that renders the self-injection process exceptionally easy and free of undesirable and dangerous side effects such as priapism, fibrosis, pain or other serious complications. In addition, ReliaJect is also useable in the delivery of compounds for certain other medical conditions. Independent clinical studies at University of California/Irvine have shown that Kinetin®, an essential growth factor, retards senescence of plants and delays age-related changes in cultured human skin cells.

Activity:

- Manufacturing
- Research & Development
- Sales & Distribution

Product / Technology type(s) covered:

- Bio
- Cosmoceuticals
- Drug delivery
- Pharmaceuticals / Therapeutics
- Technology

Therapeutic targets:

Markets Covered

a. HeadQuarter:

b. Continent(s) active:

c. Countries active:

Corporate data:

Number of Employees:

Turnover:

Amount:	Year:	Currency:

Year founded: